Urogen Pharma (NASDAQ:URGN) Shares Gap Up Following Earnings Beat

Urogen Pharma (NASDAQ:URGN) gapped up before the market opened on Tuesday following a better than expected earnings announcement. The stock had previously closed at $19.02, but opened at $19.54. Urogen Pharma shares last traded at $19.1950, with a volume of 391,591 shares changing hands.

The company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.66) by $0.12. The company had revenue of $37.84 million for the quarter, compared to analyst estimates of $39.92 million.

Key Headlines Impacting Urogen Pharma

Here are the key news stories impacting Urogen Pharma this week:

• Positive Sentiment: Q4 earnings beat — UroGen reported EPS of about ($0.54), beating consensus (−$0.66) and showing improvement from a year ago; management highlighted strong commercial momentum on the call. UroGen Pharma Ltd (URGN) Q4 2025 Earnings Call Highlights
• Positive Sentiment: ZUSDURI launch on‑track and reimbursement progress — Company says the ZUSDURI commercial launch remains on track; a permanent J‑Code became effective Jan 1, 2026, which should ease reimbursement and patient access. UroGen Announces ZUSDURI Launch is On-Track
• Positive Sentiment: Commercial traction — JELMYTO generated ~$94M in 2025 (about 7% underlying growth) and initial ZUSDURI net sales were ~$15.8M in 2025, supporting management’s growth narrative and longer‑term revenue opportunity. UroGen Announces ZUSDURI Launch is On-Track
• Positive Sentiment: Lower cost of capital — UroGen refinanced its term loan with Pharmakon Advisors at a fixed 8.25% rate and extended amortization to Q1 2030, improving liquidity and reducing near‑term cash pressure. UroGen Announces Refinanced Term Loan Agreement
• Positive Sentiment: Analyst support — D. Boral Capital reaffirmed a “buy” and set a $33 price target, signaling bullish analyst sentiment on upside from current levels. Benzinga
• Neutral Sentiment: Long‑term ambition — Management outlined a $1B peak revenue goal for ZUSDURI as adoption accelerates; this is aspirational and depends on execution and payor uptake. UroGen outlines $1B peak revenue goal for ZUSDURI
• Negative Sentiment: Revenue missed estimates — Q4 revenue of $37.84M came in below consensus (~$39.9M), which may temper near‑term upside despite the EPS beat. Urogen Pharma (URGN) Reports Q4 Loss, Beats Revenue Estimates
• Negative Sentiment: Supply‑chain / geopolitical risk — UroGen flagged that trade tensions and reliance on a global supply chain for Jelmyto and ZUSDURI could pressure margins, pipeline timelines and growth if disruptions occur. Trade Tensions Put UroGen Pharma’s Margins, Pipeline and Growth at Risk

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. Wall Street Zen raised shares of Urogen Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Oppenheimer restated an “outperform” rating on shares of Urogen Pharma in a report on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of Urogen Pharma in a report on Wednesday, January 21st. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $33.00 price objective on shares of Urogen Pharma in a report on Monday. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $33.29.

Insider Buying and Selling

In other news, insider Mark Schoenberg sold 7,373 shares of the company’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $19.69, for a total value of $145,174.37. Following the completion of the sale, the insider owned 144,985 shares of the company’s stock, valued at approximately $2,854,754.65. This represents a 4.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, General Counsel Jason Drew Smith sold 7,479 shares of Urogen Pharma stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $19.69, for a total transaction of $147,261.51. Following the completion of the transaction, the general counsel owned 51,326 shares in the company, valued at approximately $1,010,608.94. The trade was a 12.72% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 4.70% of the company’s stock.

Institutional Trading of Urogen Pharma

Several hedge funds and other institutional investors have recently bought and sold shares of URGN. Osaic Holdings Inc. increased its stake in shares of Urogen Pharma by 491.2% in the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock worth $50,000 after buying an additional 3,070 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Urogen Pharma by 27.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock worth $53,000 after purchasing an additional 486 shares during the period. State of Wyoming purchased a new position in Urogen Pharma during the 3rd quarter valued at about $66,000. Russell Investments Group Ltd. raised its position in Urogen Pharma by 1,594.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock valued at $66,000 after purchasing an additional 3,125 shares during the last quarter. Finally, Strs Ohio bought a new stake in shares of Urogen Pharma in the 3rd quarter worth approximately $76,000. Institutional investors own 91.29% of the company’s stock.

Urogen Pharma Stock Performance

The business’s 50-day moving average is $21.19 and its 200-day moving average is $20.88. The company has a market capitalization of $901.79 million, a PE ratio of -5.57 and a beta of 1.34.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.